Replies to post #222673 on Biotech Values

[DewDiligence]

Notable observation from NTGN update:

https://www.globenewswire.com/news-release/2019/03/31/1790265/0/en/Neon-Therapeutics-Presents-Updated-Data-from-Ongoing-Phase-1b-NT-001-Clinical-Trial-of-Personal-Neoantigen-Vaccine-NEO-PV-01-at-AACR-2019-Annual-Meeting.html

Several metrics that typically correlate with patient response to checkpoint inhibitors, including tumor mutation burden and tumor PD-L1, were not correlated with [durable clinical benefit] in this analysis…

Reminder: As noted earlier in this thread (#msg-144385069), this phase-1 trial does not test NEO-PV-01 monotherapy.